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A B S T R A C T   
Aims: Aceruloplasminemia is an ultra-rare neurodegenerative disorder associated with massive brain iron de-
posits, of which the molecular composition is unknown. We aimed to quantitatively determine the molecular iron 
forms in the aceruloplasminemia brain, and to illustrate their influence on iron-sensitive MRI metrics. 
Methods: The inhomogeneous transverse relaxation rate (R2*) and magnetic susceptibility obtained from 7 T MRI 
were combined with Electron Paramagnetic Resonance (EPR) and Superconducting Quantum Interference Device 
(SQUID) magnetometry. The basal ganglia, thalamus, red nucleus, dentate nucleus, superior- and middle tem-
poral gyrus and white matter of a post-mortem aceruloplasminemia brain were studied. MRI, EPR and SQUID 
results that had been previously obtained from the temporal cortex of healthy controls were included for 
comparison. 
Results: The brain iron pool in aceruloplasminemia detected in this study consisted of EPR-detectable Fe3+ ions, 
magnetic Fe3+ embedded in the core of ferritin and hemosiderin (ferrihydrite-iron), and magnetic Fe3+
embedded in oxidized magnetite/maghemite minerals (maghemite-iron). Ferrihydrite-iron represented above 
90% of all iron and was the main driver of iron-sensitive MRI contrast. Although deep gray matter structures 
were three times richer in ferrihydrite-iron than the temporal cortex, ferrihydrite-iron was already six times more 
abundant in the temporal cortex of the patient with aceruloplasminemia compared to the healthy situation (162 
µg/g vs. 27 µg/g), on average. The concentrations of Fe3+ ions and maghemite-iron in the temporal cortex in 
aceruloplasminemia were within the range of those in the control subjects. 
Conclusions: Iron-related neurodegeneration in aceruloplasminemia is primarily associated with an increase in 
ferrihydrite-iron, with ferrihydrite-iron being the major determinant of iron-sensitive MRI contrast.   
1. Introduction 
Aceruloplasminemia (OMIM #604290) is a severe adult-onset form 
of Neurodegeneration with Brain Iron Accumulation (NBIA), caused by 
homozygous or compound heterozygous mutations in the ceruloplasmin 
(CP) gene. Iron accumulation in aceruloplasminemia has been directly 
linked to its genetic background, as ceruloplasmin-mediated oxidation 
of ferrous iron (Fe2+) to ferric iron (Fe3+) is a prerequisite for transport 
of iron across cell membranes and for binding to transferrin (Miyajima 
et al., 2003). As a result of ceruloplasmin dysfunction in the brain 
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leading to insufficient cellular iron efflux, iron accumulates within 
perivascular astrocytes, with total iron concentrations reaching over 
600 µg/g in the basal ganglia (Miyajima, 2015), which is at least five 
times the normal concentration (Morita et al., 1995; Miyajima, 2015). 
However, the exact role of different iron forms in the pathophysiology 
and clinical phenotype of aceruloplasminemia is still not clear. Molec-
ular specification of the massive iron pool in the aceruloplasminemia 
brain can aid our understanding of iron related neurodegeneration, and 
perhaps improve therapeutic considerations, which are currently based 
on iron chelation. 
Among the molecular forms in which iron can be found in the brain, 
three are particularly relevant. In the healthy human brain, iron is 
predominantly stored within the core of ferritin and hemosiderin, in the 
form of Fe3+- containing ferrihydrite nanocrystals (Fe5O8H) (Sassi and 
Rosso, 2019; Dobson, 2001). These iron stores are generally regarded as 
non-damaging and are required for normal brain functions. In contrast, 
Fe2+ ions taking part in the labile iron pool have been associated with 
iron-related neuronal damage through generation of free radicals via the 
Fenton reaction (Miyajima et al., 2003; Dobson, 2001; Markesbery, 
1997). The iron-oxide magnetite (Fe3O4) is a carrier of Fe2+ and has 
been suggested to play a role in iron-related neurodegeneration (Dob-
son, 2001; Kirschvink et al., 1992). Histochemical studies in acer-
uloplasminemia have indicated an abundance of ferritin-bound iron 
(Kaneko et al., 2002, 2012), and smaller amounts of Fe2+ carriers 
(Kaneko et al., 2002; Gonzalez-Cuyar et al., 2008). However, no quan-
titative studies have been performed to further determine the molecular 
forms of iron and their distribution throughout the aceruloplasminemia 
brain. 
Iron-sensitive MRI techniques have been commonly applied as an 
indirect measure of brain iron content in neurodegenerative disorders, 
using the effect that (para)magnetic iron has on the proton nuclear 
relaxation rate (R2*) and on the magnetic susceptibility of the tissue (χ), 
which can be measured by Quantitative Susceptibility Mapping (QSM) 
(Haacke et al., 2005; Dusek et al., 2013). Although R2* mapping is 
recognized as a robust method to infer iron accumulation in brain tissue, 
it is affected by several confounders such as cell water content, the 
macromolecular pool, the degree of myelination and fiber orientation 
(Cherubini et al., 2009; Wharton and Bowtell, 2012). In particular, 
myelin and iron have the same effect on R2* values (Stüber et al., 2014). 
QSM, on the other hand, has the potential to differentiate between 
myelin and iron, based on their opposite effects on tissue susceptibility 
(Gong et al., 2019), and seems less affected by the cellular localization of 
iron (Colgan et al., 2020). Both iron-sensitive MRI techniques have been 
used for the quantitative assessment of iron in aceruloplasminemia brain 
tissue (Pan et al., 2011; Zhou et al., 2020), but only provided indirect 
information on the total iron concentrations and not their specification 
(Bulk et al., 2018). 
The primary aim of this study was to quantify different molecular 
iron forms in the aceruloplasminemia brain. For this purpose, we per-
formed Electron Paramagnetic Resonance (EPR) and Superconducting 
Quantum Interference Device (SQUID) magnetometry on ten brain re-
gions derived from a post-mortem aceruloplasminemia brain. Due to the 
rarity of the disease, aceruloplasminemia brain material is extremely 
scarce. We present a quantitative overview of Fe3+ ions detected by EPR, 
and magnetic Fe3+ embedded in ferritin cores or hemosiderin (ferrihy-
drite-iron) and oxidized magnetite/maghemite minerals (maghemite- 
iron), as detected by magnetometry. R2* and QSM maps from the same 
regions are shown with the additional aim to illustrate the extent to 
which different iron forms affect iron-sensitive MRI metrics. Since MRI is 
the major imaging modality capable of studying brain iron accumulation 
in vivo, further specification of the molecular basis of iron-sensitive MRI 
contrast is key to gain more in-depth pathophysiological insights into 
different clinical stages of iron-related neurodegeneration. 
2. Methods 
2.1. Brain tissue selection 
Formalin-fixed brain slices of one end-stage aceruloplasminemia 
patient (52 years,male) were obtained from the Department of Pathol-
ogy, Erasmus University Medical Center, Erasmus MC, Rotterdam, The 
Netherlands. His neurological phenotype has been previously published, 
and was characterized by orofacial dyskinesia, chorea, dystonia, 
dysarthria and a predominantly ataxic gait disturbance (Vroegindeweij 
et al., 2015, 2017; Kerkhof and Honkoop, 2014). He gradually deterio-
rated despite combined iron chelation therapy with deferiprone and 
phlebotomy (Vroegindeweij et al., 2020). He became bedridden and 
died from bronchopneumonia years after the onset of neurological 
symptoms. The brain slices had been stored in formalin for 5 years. 
Tissue blocks of approximately 30 × 30 × 10 mm3 were dissected, 
including the basal ganglia, thalamus, red nucleus, dentate nucleus, 
superior- and middle temporal gyrus and white matter. Ceramic tools 
were used to prevent metal contamination of the samples. The study was 
approved by the Medical Ethics Review Board of the Erasmus MC. The 
patient’s legal representative provided written informed consent. 
2.2. MRI data acquisition and data analysis 
Before MRI, the dissected tissue blocks were rehydrated in phosphate 
buffered saline (PBS) for 24 h and immersed in a proton-free solution 
(Fomblin LC08, Solvay). This is known to partially restore the transverse 
relaxation times, which are typically shortened by fixation (Shepherd 
et al., 2009). ICP-MS detected iron traces up to 3.5 µg/ml in the formalin 
solution, likely due to leakage of iron from the tissue over time. MRI 
scans were performed at room temperature on a 7 T preclinical scanner 
(Bruker Biospin, Ettlingen, Germany) using a 38-mm quadrature RF coil. 
The MR acquisition consisted of a three-dimensional multi-gradient- 
echo sequence with eight equally spaced echoes. First echo-time was 
1.96 ms, echo spacing was 2.21 ms, repetition time was 130.4 ms, flip 
angle was 25◦, 150 µm3 isotropic spatial resolution. 20 averages were 
acquired. The total acquisition time was 3 h 54 min. 
R2* (1/T2*) maps were obtained by fitting the signal decay of the 
magnitude images to a mono-exponential decay function, excluding the 
echoes that hit the noise floor (Bouhrara et al., 2015). The assumption of 
mono-exponentiality was tested and verified in all tissue blocks. A de-
viation from mono-exponentiality was observed in a few, regionally a- 
specific, pixels in the tissue block containing the basal ganglia (Sup-
plementary material, Fig. S1). While the presence of a second compo-
nent in the echo decay is relevant in the case of a microscopically 
inhomogeneous distribution of iron forms, given the scarcity of the 
pixels featuring a bi-exponential decay, and the limited number of 
echoes over which the fit could be performed, we report here the results 
of the mono-exponential fit, also for the block containing the basal 
ganglia. A dominant mono-exponential component hints at the fact that 
one form of iron may be the main driver of R2* relaxation. 
Susceptibility values (χ) were obtained from the eight-echoes phase 
images of the multi-gradient-echo data, with the STI-Suite software 
(version 2.2) (Li et al., 2014). Phase unwrapping of the measured phase 
images and removal of the background field was done with the iHAR-
PERELLA algorithm (Li et al., 2015), while magnetic susceptibility 
estimation and streaking artifact correction was performed with the 
‘iLSQR’ algorithm (Li et al., 2015). Raw susceptibility values are re-
ported, as no reference region was available in these small tissue sam-
ples. Regions of interest (ROIs) were manually drawn within each deep 
gray matter region, middle temporal gyrus and temporal white matter. 
For each ROI, mean R2* and magnetic susceptibility values were 
reported. 
Additional MR images that had been previously acquired (Bulk et al., 
2018) on tissue blocks containing the temporal cortex and the striatum 
of two control subjects are used as references to illustrate the effect of 
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iron accumulation in the aceruloplasminimia brain on MRI maps. These 
control tissue blocks had been scanned with an acquisition protocol as 
described above, with the exception of the echo timing, which was 
increased as the iron concentration was much lower in these control 
cases: the first echo time was 12.5 ms long, and the inter-echo time was 
10.7 ms. 
2.3. EPR experiments and spectra fitting 
After MRI, subsections of approximately 40 mg were taken from each 
gray and white matter structure in the tissue blocks (Fig. 1). The 
resulting subsections were prepared for EPR as previously described 
(Kumar et al., 2016). The 9 GHz continuous wave EPR measurements 
were performed at 6 K using an ELEXSYS E680 spectrometer (Bruker, 
Rheinstetten, Germany) equipped with a rectangular cavity. The mi-
crowave frequency was 9.4859 GHz, modulation frequency 90 kHz, 
power attenuation 20 dB, receiver gain 60 dB and modulation amplitude 
6 Gpp. Power attenuation was chosen after a progressive power satu-
ration experiment (Supplementary material, Fig. S2). The accumulation 
time was approximately five minutes per spectrum. 
Fig. 2 shows a baseline corrected EPR spectrum of the tissue block 
extracted from the putamen. While the spectra consisted of several 
bands, in this work, we focused on the low field g’=4.3 band, which 
originates from high-spin Fe3+ complexed in a site of low symmetry 
(Kumar et al., 2016). A close look at the temperature dependence of the 
amplitude band suggests the presence of a weak antiferromagnetic 
coupling (Supplementary material, Fig. S3). 
The g’=4.3 bands detected in each sample were fit to the spin 
Hamiltonian which describes high-spin Fe3+ (Kumar et al., 2016). EPR 
spectra simulations and fitting were done with EasySpin version 5.2.28 
Fig. 1. Pipeline of the experimental proto-
col. In this example, the basal ganglia 
(caudate nucleus – CN, putamen – PU, 
globus pallidus – GP), were dissected from 
the appropriate brain slab and prepared for 
MRI. Following MRI, small subsections were 
taken from each basal ganglia structure and 
prepared for EPR. Regions of interest (ROIs) 
on the MRI were matched with the EPR 
sampling locations. For SQUID, subsections 
of tissue were taken adjacent to the sampling 
locations for EPR. Scale bar in the bottom 
figures, 1 cm.   
Fig. 2. Determination of Fe3+ ions by Electron Paramagnetic Resonance (EPR) 
at 6 K. First derivative, baseline corrected EPR spectrum of the putamen. The 
spectrum consists of several bands: a g’~7 poorly defined signal, a weak band 
at g’=6, an intense band at g’=4.3, a largely asymmetric band around g’=2.04, 
and a narrow band at g’=2.008. 
L.H.P. Vroegindeweij et al.                                                                                                                                                                                                                    
NeuroImage: Clinical 30 (2021) 102657
4
(Stoll and Schweiger, 2006). Fitting parameters and examples of the 
fitted spectra are shown in the Supplementary material (Table S1 and 
Fig. S4). The Fe3+ concentration of each sample was calculated by taking 
the second integral of the fitted spectrum and comparing it to the second 
integral of a reference solution Fe-EDTA of known Fe3+ concentration 
(35.7 µM). 
2.4. Magnetometry experiments 
Following EPR experiments, subsections were taken from the 
caudate nucleus, putamen, substantia nigra, thalamus, red nucleus, 
dentate nucleus, temporal cortex and white matter, mostly adjacent to 
the sampling locations for EPR. The total volume of specimens for each 
brain region was approximately 10 × 10 × 10 mm3. The globus pallidus 
was not included because of its smaller volume. Tissue samples were 
removed from formalin, frozen in liquid nitrogen, and freeze-dried. The 
brain material was subsequently pelleted and placed in the sample 
holder of a Superconducting Quantum Interference Device (SQUID) 
magnetometer. 
Isothermal Remanent Magnetization (IRM) curves were acquired 
with a Quantum Design MPMS-XL SQUID magnetometer with the 
Reciprocating Sample Option probe, as reported previously (Bulk et al., 
2018; Kumar et al., 2016), to explore whether the samples retained 
magnetization outside of an external magnetic field following stepwise 
exposure to higher magnetic field strengths at a constant temperature 
(Hautot et al., 2007, 2003). Two IRM curves were acquired: one at 5 K, 
which can report on ferrihydrite, the mineral found in the core of ferritin 
proteins and hemosiderin aggregates; and a second at 100 K, which 
saturated around 250 mT, indicative of magnetite or its oxidation 
product, maghemite. An example of the IRM curves for one of the 
samples is shown in Fig. 3. The IRM values were obtained after dividing 
the raw magnetic moment by the wet weight of the sample. Saturation 
IRM values (SIRM) were extracted by fitting the IRM curves to an offset- 
corrected Langevin model, as in our previous work (Bulk et al., 2018). 
Ferrihydrite and maghemite concentrations were estimated by 
dividing the SIRM values by the saturation magnetization of the specific 
mineral: 0.62 Am2/kg for ferrihydrite (Makhlouf et al., 1997), and 74 
Am2/kg for maghemite (Cao et al., 2016). Maghemite was chosen 
instead of magnetite, due to the high chance of sample oxidation during 
tissue processing. Subsequently, the ferrihydrite-iron and maghemite- 
iron concentrations were calculated by multiplying the mineral con-
centration by the iron mass-ratio for the given mineral. Concentrations 
of Fe3+, ferrihydrite-iron and maghemite-iron that had been previously 
obtained under identical conditions from the temporal cortex of healthy 
controls are provided for comparison (Bulk et al., 2018). 
Raw data post-processing of MRI, EPR and SQUID data was per-
formed with an in-house written code in MatlabR2016a. Raw data ob-
tained in this study are downloadable at the link: https://doi.org/ 
10.17632/8b3fvc3h3f.1 
3. Results 
Table 1 provides an overview of all data collected from the acer-
uloplasminemia brain. The highest R2* values were found in the lateral 
division of the thalamus and substantia nigra. On average, R2* values 
within deep gray matter structures in aceruloplasminemia were over 
two times higher than those obtained from the temporal cortex. The 
deep gray matter structures in aceruloplasminemia had at least a three- 
fold increase in relaxation rates with respect to the close-by white 
matter, while in the temporal cortex the relative gray matter/white 
matter relaxation rate was reversed. Higher relaxation rates were 
observed in the white matter, which indicates a large fraction of iron 
being embedded in myelin. In the control subjects, both the white matter 
of the internal capsule and of the temporal lobe showed higher relaxa-
tion rates compared to the close-by gray matter (Fig. 4), but in all re-
gions the relaxation rates were substantially lower than for the 
aceruloplasminemia case. Susceptibility values in aceruloplasminemia 
were only partially in accordance with the pattern of iron accumulation 
as suggested by the R2* maps and were more heterogeneous within the 
structures (Fig. 4). Notable exceptions were the dentate nucleus, parts of 
the putamen and the temporal white matter, where a striking para-
magnetic component was observed compared to close-by structures. 
Ferrihydrite-iron was the most abundant form of iron in all investi-
gated brain regions in aceruloplasminemia and represented 91–98% of 
all iron (Table 1). Mean concentrations of ferrihydrite-iron in the deep 
gray matter reached over 500 µg/g wet weight and were three times 
higher compared to the temporal cortex, which already exceeded the 
healthy situation by six times, on average. The amount of Fe3+ ions, 
detectable by EPR, and maghemite-iron in the temporal cortex of the 
patient with aceruloplasminemia was within the range of concentrations 
that had been detected in the control subjects. Although the 
ferrihydrite/maghemite-iron ratio was highly variable among struc-
tures, ferrihydrite-iron was at least three orders of magnitude more 
abundant than maghemite-iron, on average. 
The distribution of Fe3+ ions and iron mineralization products in the 
aceruloplasminemia brain is visualized in Fig. 5. The globus pallidus and 
medial division of the thalamus, together with regions in the brain stem 
and cerebellum, showed the highest EPR-detectable Fe3+ concentration. 
The distribution of maghemite-iron appeared partially in accordance 
with this pattern, with the medial division of the thalamus, red nucleus, 
substantia nigra and dentate nucleus being the richest in this mineral 
form of iron. Maghemite levels in the lateral division of the thalamus 
and the putamen were below the detection limit of the technique. 
4. Discussion 
In this work, the iron-sensitive metrics R2* and χ, obtained from 7 T 
MRI, were combined with Electron Paramagnetic Resonance (EPR) and 
SQUID magnetometry to specify and quantify the different iron forms in 
Fig. 3. Determination of ferrihydrite and maghemite by Isothermal Remanent Magnetization (IRM). IRM curves of the dentate nucleus (DN) at 5 K (left) and 100 K 
(right). The IRM curve at 100 K saturates around 0.25 T, which is a strong indication for the presence of magnetite or maghemite. 
L.H.P. Vroegindeweij et al.                                                                                                                                                                                                                    
NeuroImage: Clinical 30 (2021) 102657
5
the aceruloplasminemia brain. We detected and quantified ferrihydrite- 
iron – which is a measure of iron stores in the brain, maghemite-iron – an 
iron form that is recently attracting the attention of MR-physicists and 
biologists due to its potential neurotoxicity and the influence that it may 
have on MRI signal dephasing, and an EPR-sensitive pool of Fe3+ ions. 
The comparison between R2* and QSM maps indicated that a (para) 
magnetic source is driving the increase in relaxation rate in both gray 
and white matter structures in aceruloplasminemia. We ascribe this 
source to iron, mainly ferrihydrite-iron. The R2* values showed that the 
lateral division of the thalamus, the substantia nigra, the dentate nu-
cleus, and the red nucleus were heavily iron-loaded, which is in agree-
ment with a recent in vivo study in aceruloplasminemia (Zhou et al., 
2020). From the QSM maps, an increase in the paramagnetic signal was 
only observable in a few selected areas. Although QSM has the potential 
to more specifically identify the underlying source of R2* increase, our 
reconstructions suffered from artefacts and the quality was not sufficient 
for quantitative analysis. These artefacts were likely caused by the large 
heterogeneity of iron accumulation within structures and the extremely 
short proton relaxation time as a result of the extremely high iron con-
centrations that impaired the detection of the signal. QSM re-
constructions in aceruloplasminemia might therefore benefit from lower 
magnetic field strengths or shorter echo times, to partially mitigate these 
effects. 
Of the three iron forms detected in the aceruloplasminemia brain, 
more than 90% was found to be associated with the ferritin storage 
protein and hemosiderin (ferrihydrite-iron). These findings agree with 
earlier histochemical studies of aceruloplasminemia brain tissue that 
showed the abundance of iron aggregates rich in Fe3+ that strongly 
reacted to ferritin light chain antibody (Kaneko et al., 2002, 2012), and 
observations in healthy brain tissue (Möller et al., 2019). The concen-
trations of ferrihydrite-iron in the basal ganglia of our patient with 
aceruloplasminemia could not be appropriately compared with results 
that had been previously obtained from the basal ganglia of healthy 
subjects and patients with neuroferritinopathy (Hautot et al., 2007), due 
to substantial methodological differences between studies. The amount 
of ferrihydrite-iron in the temporal cortex of aceruloplasminemia, 
though, was six times higher than in healthy subjects and almost four 
times higher compared to patients with advanced Alzheimer’s disease 
that were measured under identical conditions, on average (Bulk et al., 
2018; van der Weerd et al., 2020). Although these comparisons are 
limited to the temporal cortex, which is on average three times less rich 
in iron than the deep gray matter structures in aceruloplasminemia, they 
illustrate once more the severity of iron overload in the disease. 
The distribution of ferrihydrite-iron throughout the brain in acer-
uloplasminemia did not reflect the total iron distribution in healthy 
brain tissue. While in normal ageing ferrihydrite-iron is most abundant 
in the globus pallidus and substantia nigra (Haacke et al., 2005), in this 
aceruloplasminemia brain very high levels of ferrihydrite-iron were 
detected in the red nucleus, caudate nucleus and thalamus. In addition, 
the thalamus showed a striking lateralization, with the lateral part being 
far more abundant in ferrihydrite-iron than the medial part of the 
structure. This may be explained by specific pathways that have been 
recently highlighted as possibly involved in iron transport between the 
caudate nucleus and the pulvinar nucleus within the lateral division of 
the thalamus (Zhou et al., 2020). The internal medullary lamina of the 
thalamus might additionally act as a barrier to prevent penetration of 
iron into the medial part of the structure (Kim et al., 2017). Although it 
should be noted that the globus pallidus was not assessed by magne-
tometry in this study, focal demyelination and iron accumulation with a 
preference for the pulvinar thalamus and caudate nucleus has also been 
described in patients with multiple sclerosis (Hagemeier et al., 2013; 
Haider et al., 2014), in which neurodegeneration and atrophy of these 
structures has been associated with disease progression and cognitive 
disturbances (Haider et al., 2014). Although this suggests a specific role 
of the caudate nucleus and (pulvinar) thalamus in neuroinflammation 
and neurodegeneration, different patterns of iron accumulation have 
been observed in Parkinson’s disease, multiple system atrophy, pro-
gressive supranuclear palsy (Han et al., 2013), and other NBIA disorders 
(Kruer et al., 2012), of which the clinical relevance remains to be 
elucidated. 
The above-mentioned lateralization within the thalamus, which was 
observed with quantitative MRI, EPR and SQUID magnetometry, is in 
accordance with previous in vivo MRI findings in aceruloplasminemia 
(Miyajima, 2015; Vroegindeweij et al., 2017; Kim et al., 2017). The 
relatively high R2* values obtained from the lateral division of the 
thalamus appeared to be driven by the large amount of ferrihydrite-iron 
in this region, while the medial part of the thalamus showed a lower R2* 
value despite being richer in maghemite-iron and EPR-detectable Fe3+
ions. Although the magnetization of maghemite is over two orders of 
magnitude higher compared to the one of ferrihydrite, its influence on 
iron-sensitive MRI remained limited due to the much lower concentra-
tion of maghemite nanocrystals compared to ferrihydrite (Dobson et al., 
2009). Even though these observations do not exclude that ferrihydrite- 
iron and maghemite-iron may contribute together to the increase of 
tissue magnetic susceptibility, ferrihydrite-iron likely remains the main 
driver of MRI susceptibility contrast in extremely iron-loaded cases. 
The potential role of maghemite-iron in the pathogenesis of acer-
uloplasminemia should not be discarded purely based on its limited 
contribution to the total brain iron pool. Absolute SIRM values detected 
at 100 K in aceruloplasminemia were approximately two orders of 
magnitude higher than those reported in healthy subjects, at room 
temperature (Gilder et al., 2018), which suggests that also maghemite- 
iron levels may have increased as a result of iron overload in acer-
uloplasminemia. On the other hand, the concentration of maghemite- 
iron detected in the temporal cortex of aceruloplasminemia was not 
increased compared to healthy controls and advanced cases of 
Table 1 
Overview of MRI, EPR and SQUID results obtained from the aceruloplasminemia brain.   
7 T MRI EPR SQUID magnetometry  
Structure R2*(ms− 1) χ(ppm) Fe3þ(µg/g) Ferrihydrite-iron (µg/g) Maghemite-iron(ng/g) Fh-iron(%) 
Red nucleus  0.3760  0.0033  24.15 1064.84 109.28 98 
Thalamus L  0.4350  0.0103  15.00 709.72 UD 98 
Caudate nucleus  0.2826  − 0.0048  11.34 635.98 22.68 98 
Dentate nucleus  0.3827  0.0501  20.88 319.58 90.27 94 
Putamen  0.3254  0.0026  14.39 317.50 UD 96 
Thalamus M  0.2118  − 0.0474  28.62 290.01 259.07 91 
Substantia nigra  0.4230  − 0.0062  20.93 247.35 61.30 92 
Temporal cortex  0.1400  − 0.0124  9.21 5.29 (2.0–10.0) 161.68 26.57 (7.24–39.31)  23.40 14.11(0–45.90) 95 
Globus pallidus  0.3338  − 0.0014  34.06 NA NA – 
White matter  0.1696  0.0565  8.12 175.43 13.77 96 
R2* and χ results are shown as mean of the ROIs shown in Fig. 4. Concentrations are given per gram wet weight tissue, and previously obtained average (range) 
concentrations in the healthy brain (Bulk et al., 2018) are presented in italics. Abbreviations: Fh – ferrihydrite, M – medial division of the thalamus, L – lateral division 
of the thalamus, UD – undetectable, NA – not available. 
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Alzheimer’s disease that were measured under identical conditions 
(Bulk et al., 2018; van der Weerd et al., 2020). In addition, in contrast to 
ferrihydrite-iron, the regional distribution of maghemite-iron in the 
aceruloplasminemia brain was not substantially different from that of 
healthy controls (Gilder et al., 2018), with the cerebellar and brain stem 
nuclei being relatively rich in this magnetic carrier, although thalamic 
structures were not specifically investigated by previous studies (Gilder 
et al., 2018). The preserved distribution of maghemite-iron throughout 
the severely diseased aceruloplasminemia brain rather questions its 
biological relevance, which has already been a subject of debate in other 
iron-related neurodegenerative conditions (Bulk et al., 2018; Kumar 
et al., 2016; Hautot et al., 2007, 2003; Pankhurst et al., 2008). Being 
able to distinguish between the contribution of ferrihydrite-iron and 
maghemite-iron to MRI contrast in vivo is important to unravel a possible 
cause-effect relationship between the amount of maghemite-iron and 
the severity of neurological manifestations, which might shed new light 
Fig. 4. Comparison of quantitative MRI results. The R2* and QSM maps are shown with the outlined regions of interest (ROIs) in the temporal cortex (1) and white 
matter (2) (A, B), putamen (3), caudate nucleus (4) and globus pallidus (5) (D, E), dentate nucleus (6) (G, H), thalamus (7–ateral division,8–medial division), 
substantia nigra (9) and red nucleus (10) (I, J) in aceruloplasminemia. Note that for the red nucleus, the susceptibility signal was predominantly masked out (J). R2* 
maps of the temporal cortex (1) and white matter (2) (C), putamen (3) and caudate nucleus (4)(F) of a control subject are provided for comparison. Scalebar, 1 cm. 
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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on the pathophysiological role of maghemite-iron in iron-related 
neurodegeneration. 
The EPR-detected Fe3+ ions are complementary to the two above- 
mentioned iron forms and may account for a part of the labile iron 
pool, which is implicated in the formation of reactive oxygen species and 
for monomeric iron sites in the ferritin shell that are responsible for 
ferroxidase activity. Although EPR also has the potential to detect 
ferrihydrite-iron and maghemite-iron, the signal from these minerals is 
optimal at higher temperatures than used here (Wajnberg et al., 2001), 
and would require a much larger sample mass than what employed by 
us. Given its low abundance and relatively small magnetic moment, it is 
unlikely that Fe3+ ions significantly affect the MRI signal in 
aceruloplasminemia. 
Our work has some limitations, the first being the long-term formalin 
fixation of the tissue. Since formalin fixation is known to reduce total 
tissue iron content and may have a detrimental effect on protein con-
formations (Schrag et al., 2010; Gellein et al., 2008; Ghosh et al., 2010; 
Kalyanaraman et al., 2019), it is likely that the presented absolute 
concentrations of Fe3+ ions, ferrihydrite-iron and maghemite-iron in the 
aceruloplasminemia brain are underestimated compared to in vivo. In 
addition, formalin fixation has likely increased the R2* values, compared 
to in vivo conditions (Birkl et al., 2016). Therefore, future studies should 
aim to minimize the duration of formalin fixation (van der Weerd et al., 
2020), and ideally include both aceruloplasminemia and control brain 
tissue to enable more in-depth analyses of the exact relationship be-
tween the different molecular forms of iron that are present in healthy 
and severely diseased states. On the other hand, the spatial distribution 
of the different iron forms, as presented in our work, is not significantly 
affected by prolonged formalin fixation (Gilder et al., 2018). This is 
confirmed by the non-uniform distribution of iron within the thalamus 
in our study, which is in accordance with previous in vivo MRI findings in 
aceruloplasminemia (Miyajima, 2015; Vroegindeweij et al., 2017; Kim 
et al., 2017). Given the short T2* values that characterize the acer-
uloplasminemia brain, future studies should additionally aim to employ 
data acquisition techniques that allow a shorter first echo-time and 
inter-echo spacing, e. g. radial k-space coverage. The lack of T2 maps 
represents another limitation of our current work, since spin-echo decay 
could add valuable information on the degree of iron aggregation e.g. in 
the form of hemosiderin (Jensen et al., 2010), and the ratio between R2* 
and R2 could reveal important information on the effective size of the 
iron-rich compartments (Lee et al., 2018). Moreover, the reported 
ferrihydrite-iron and maghemite-iron concentrations should be consid-
ered as approximate rather than absolute values, given the assumptions 
that had to be made to obtain these iron concentrations from the SIRM 
values. However, we believe that reporting iron concentrations instead 
of SIRM values can help guiding the interpretation of the results in the 
Fig. 5. Distribution of different iron forms in aceruloplasminemia brain tissue. Abbreviations: DN – dentate nucleus, SN – substantia nigra, RN – red nucleus, THM – 
medial division of the thalamus, THL – lateral division of the thalamus, CN – caudate nucleus, GP – globus pallidus, PU – putamen, WM – white matter, GM – gray 
matter. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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context of biology. Finally, since our results are based on a single patient 
study, generalization to other cases should be done carefully. It should 
be noted, though, that the rarity of aceruloplasminemia makes the tissue 
availability a challenge, as illustrated by the fact that only six other 
autopsy cases have been published over decades (Morita et al., 1995; 
Kaneko et al., 2002, 2012; Kawanami et al., 1996). 
In conclusion, ferrihydrite-iron is the major determinant of iron- 
sensitive MRI contrast, and is the most abundant iron form in the 
aceruloplasminemia brain. Among the studied regions, the lateral divi-
sion of the thalamus, the red nucleus and the basal ganglia contained the 
highest amounts of ferrihydrite-iron. The maintenance of ferritin as the 
major iron storing protein in extremely iron-loaded brain tissue, as 
observed in our study, has major implications for the concept of iron 
chelation as the main treatment for aceruloplasminemia and other NBIA 
disorders. In particular, deferiprone is currently being exploited to treat 
several NBIA diseases (Vroegindeweij et al., 2020; Klopstock et al., 
2019). Deferiprone is the only iron chelator known to date that is 
capable of transporting iron across cell membranes and across the blood 
brain barrier. As it selectively binds Fe3+ and is capable of directly 
removing Fe3+ ions from the core of ferritin (Bou-Abdallah et al., 2011), 
our findings pathophysiologically support the clinical benefit of defer-
iprone that has been reported in patients with aceruloplasminemia and 
other NBIA disorders (Vroegindeweij et al., 2020; Klopstock et al., 
2019), and highlight the potential of specifically quantifying 
ferrihydrite-iron in vivo to improve the use of iron-sensitive MRI metrics 
as an outcome measure of iron chelation therapy. 
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